Amgen Inc (AMGN) — 分析摘要
Amgen Inc（AMGN）的市值为237.52十亿美元，最近一年的营收同比增长了+10.0%。净利润率为21.0%。当前市盈率为27.2倍。
核心要点
- 营收同比变化+10.0%
- 净利润率21.0%
- 市盈率27.2倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，AMGN的营收增长为+10.0%，市盈率为27.2倍。
Amgen Inc (AMGN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
D/E 为 4.9x — 财务杠杆偏高
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
31,500
总部
THOUSAND OAKS, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$10.08
股息收益率
2.29%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。